Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Four doses of Eli Lilly's diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug Administration's website showed.

Some doses of Lilly's Mounjaro in tight supply through April, US FDA says

Citi analyst Andrew Baum raised his price target on Lilly stock to $895 from $675, citing increased sales expectations for a new drug.

Eli Lilly's Ozempic Competitors Face Risks. Why the Stock Has More Upside.

Advanced Micro Devices

Salesforce

CrowdStrike

CyberArk Software

Intuitive Surgical

monday.com

Cloudflare

Uber

Meta Platforms and AMD are among several leading stocks finding support around the 10-week line, creating potential buying opportunities.

Meta Platforms, AMD Lead 10 Stocks Showing This Bullish Action

Eli Lilly shares have climbed in the triple digits over the past year, and earnings have soared too. The company sells two of the world's most sought-after products right now: weight-loss drugs.

Is It Too Late to Buy Eli Lilly Stock?

Costco

Vertex Pharmaceuticals

The "Magnificent Seven" are not the only stocks worth investing in. Vertex Pharmaceuticals and Eli Lilly are launching in-demand medicines.

Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead

AbbVie

HCA Healthcare

Novo Nordisk

UnitedHealth Group

These seven healthcare companies are industry and market leaders. They generally present excellent long-term prospects, too.

Meet The "Magnificent Seven" of Healthcare Stocks

Shopify

The pharmaceutical and e-commerce industries have proven to be resilient places to invest. Eli Lilly is riding a wave of sales from new blockbuster drugs on top of its flagship products.

Have $1,500? 2 Top Growth Stocks to Buy Right Now for 2024 and Beyond

Viking Therapeutics

Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound, have already generated billions of dollars in revenue but this may be the tip of the iceberg. Viking Therapeutics' VK2735 has emerged as a strong contender in the GLP-1 drug market, with promising weight loss results in clinical studies.

Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data

CRISPR Therapeutics

The sky is the limit for CRISPR Therapeutics. Eli Lilly is a growth machine that will not stop anytime soon.

3 Unstoppable Stocks to Buy Hand Over Fist in April

Catalent

DexCom

Stevanato Group SpA

The diabetes and obesity markets are large and growing, with an estimated total long-term addressable market of $100 billion in the US alone. Denmark's Novo Nordisk and US-based Eli Lilly are leading pharmaceutical companies in the development of GLP-1-based treatments for diabetes and obesity.

International Companies Drive Diabesity Innovation

Bristol-Myers

Halozyme Therapeutics

Biotech is an industry full of opportunity. It's also known as one of the riskiest sectors to invest in.

The 3 Best Biotech Stocks to Buy in Q2 2024

Eli Lilly's stock price rise continues unabated in 2023, backed by strong topline growth in 2023 and a sunny outlook for 2024. Its diabetes treatments look particularly encouraging, with Mounjaro's 11x revenue increase last year and a great start to Zepbound at the end of 2023. While its market multiples look stretched for now, over the medium to long term, they too look better and the stock's exceptional long-term performance is hard to ignore.

Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets

Alphabet

ServiceNow

Many companies benefitting tremendously from the proliferation of artificial intelligence. But so far, only a relatively small number of stocks, such as Nvidia (NASDAQ: NVDA ), Microsoft (NASDAQ: MSFT ) and Super Micro (NASDAQ: SMCI ), have received a sizable boost from the trend.

The 3 Biggest Beneficiaries of the Massive AI-Driven Growth Opportunities

Berkshire Hathaway has a sizeable lead in market cap over Eli Lilly. Investors have been paying a much bigger premium for Eli Lilly, however, than they have for Berkshire.

Eli Lilly vs. Berkshire Hathaway: Which Stock Will Become the Next Member of the $1 Trillion Club?

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

Regeneron Pharmaceuticals

Shares of Eli Lilly and Regeneron have risen sharply thanks to their strong results and product approvals. Though both drugmakers could undertake stock splits, their prospects don't depend on their doing so.

Stock-Split Watch: Are These 2 Top Growth Stocks Next?

Altimmune

Amgen

Madrigal Pharmaceuticals

Rhythm Pharmaceuticals

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are answering the urgent need for effective solutions with a new generation of weight loss drugs capable of achieving previously unattainable levels of weight reduction.

7 Stocks That Will Drive the Weight Loss Drugs Market

The stocks known as the Magnificent Seven have led the S&P 500 higher over the past year. One company that isn't in this group has outperformed most of the Magnificent Seven in that time period.

Prediction: This Will Be the Next "Magnificent Seven" Stock

The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the dominance of Novo Nordisk and Eli Lilly is unlikely to be toppled anytime soon.

Here's Why Ozempic And Mounjaro Rivals Won't Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon

In the most recent trading session, Eli Lilly (LLY) closed at $774.90, indicating a +0.23% shift from the previous trading day.

Eli Lilly (LLY) Advances While Market Declines: Some Information for Investors

Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the way.

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

AstraZeneca

Bayer AG

Bicycle Therapeutics Plc - ADR

Exelixis

Fusion Pharmaceuticals

Merck

Novartis

Takeda Pharmaceutical

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

2 More Potential Biotech Buyout Targets

Demand for obesity and diabetes treatments such as Ozempic, Mounjaro, and Wegovy is off the charts. Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and diabetes.

Novo Nordisk and Eli Lilly May Finally Have Some Real Competition

Microsoft

Microsoft wants to help you become more productive with artificial intelligence. Eli Lilly's new weight loss treatment could usher in a $100 billion market for anti-obesity drugs.

News for Eli Lilly Stock (LLY)